S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
Log in
NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

Top-Rated Stocks  
$99.61
-3.41 (-3.31 %)
(As of 10/21/2020 05:02 PM ET)
Add
Compare
Today's Range
$99.20
Now: $99.61▼
$103.85
50-Day Range
$72.92
MA: $90.28▼
$108.43
52-Week Range
$35.25
Now: $99.61▼
$110.74
Volume1.03 million shs
Average Volume1.96 million shs
Market Capitalization$14.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Read More
Exact Sciences logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.25 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
Previous Symbol
CUSIP30063P10
CIK1124140
Webwww.exactsciences.com
Phone608-535-8815
Employees4,110

Debt

Debt-to-Equity Ratio0.62
Current Ratio6.77
Quick Ratio6.40

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$876.29 million
Price / Sales17.07
Cash FlowN/A
Price / Cash FlowN/A
Book Value$17.62 per share
Price / Book5.65

Profitability

EPS (Most Recent Fiscal Year)($1.49)
Net Income$-83,990,000.00
Net Margins-13.65%
Return on Equity-13.32%
Return on Assets-7.59%

Miscellaneous

Outstanding Shares150,167,000
Market Cap$14.96 billion
Next Earnings Date10/29/2020 (Confirmed)
OptionableOptionable
$99.61
-3.41 (-3.31 %)
(As of 10/21/2020 05:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

How has Exact Sciences' stock been impacted by Coronavirus?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 72.3% and is now trading at $99.61.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Exact Sciences?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Exact Sciences.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Exact Sciences.

How can I listen to Exact Sciences' earnings call?

Exact Sciences will be holding an earnings conference call on Thursday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its earnings results on Thursday, July, 30th. The medical research company reported ($0.58) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.62) by $0.04. The medical research company had revenue of $268.87 million for the quarter, compared to analysts' expectations of $229.62 million. Exact Sciences had a negative return on equity of 13.32% and a negative net margin of 13.65%.
View Exact Sciences' earnings history.

What price target have analysts set for EXAS?

14 equities research analysts have issued 1-year target prices for Exact Sciences' stock. Their forecasts range from $70.00 to $127.00. On average, they expect Exact Sciences' share price to reach $107.14 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price.
View analysts' price targets for Exact Sciences.

Who are some of Exact Sciences' key competitors?

Some companies that are related to Exact Sciences include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 54, Pay $1.82M)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 42, Pay $701.77k)
  • Ms. Ana Hooker, Sr. VP of Operations (Age 54, Pay $627.49k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 55, Pay $741.87k)
  • Mr. Jake Orville, Sr. VP of Pipeline (Age 46, Pay $769.63k)
  • Mr. G. Bradley Cole, Gen. Mang. of Precision Oncology (Age 64, Pay $1.23M)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Factory Mutual Insurance Co. (0.51%), Peregrine Capital Management LLC (0.16%), Thompson Investment Management Inc. (0.10%), Envestnet Asset Management Inc. (0.09%), CWM LLC (0.08%) and Resources Investment Advisors LLC. (0.06%). Company insiders that own Exact Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including American National Bank, International Assets Investment Management LLC, Capital Investment Advisory Services LLC, Thompson Investment Management Inc., Nisa Investment Advisors LLC, Gofen & Glossberg LLC IL, Vigilare Wealth Management, and Fluent Financial LLC. Company insiders that have sold Exact Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences.

Which major investors are buying Exact Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Factory Mutual Insurance Co., Envestnet Asset Management Inc., CWM LLC, Canal Capital Management LLC, Sanders Morris Harris LLC, Meridian Wealth Management LLC, and Redpoint Investment Management Pty Ltd.
View insider buying and selling activity for Exact Sciences.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $99.61.

How big of a company is Exact Sciences?

Exact Sciences has a market capitalization of $14.96 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Exact Sciences employs 4,110 workers across the globe.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.

This page was last updated on 10/21/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.